Spis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załączników:
  1. SFA_Sales_Revenues_January_2026_EN_espi.pdfNotification for sales revenues for January 2026

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 81 / 2026
Date of issue: 2026-02-20
Short name of the issuer
SOPHARMA AD
Subject
Notification for sales revenues for January 2026
Official market - legal basis
Art. 56. 1. 2 of Act on Public Offering
Unofficial market - legal basis
Contents of the report:
Sofia, Bulgaria, February 20, 2026 – According to the requirements of Art. 100t of the Law on Public Offering of Securities (LPOS), “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies, that January 2026 the Company recorded a decrease in sales of 37% compared to the same month of the previous year, incl. 64% decrease in domestic sales and 21% decrease in export sales.
Annexes
File Description
SFA_Sales_Revenues_January_2026_EN_espi.pdf
SFA_Sales_Revenues_January_2026_EN_espi.pdf		 Notification for sales revenues for January 2026

SOPHARMA AD
(fullname of the issuer)
SOPHARMA AD Farmaceutyczny (far)
(short name of the issuer) (sector according to clasification
of the WSE in Warsow)
1220 Sofia
(post code) (city)
IlienskoShosse 16
(street) (number)
+359 2 813 42 00 +359 2 936 02 86
(phone number) (fax)
(e-mail) (web site)
nd
(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Date Name Position / Function Signature
2026-02-20 Ognian Ivanov Donev Executive Director
20260220_130529_1197793037_SFA_Sales_Revenues_January_2026_EN_espi.pdf

Pobierz